SCHEMBL6976410

SCHEMBL6976410

CCCC1=CC(=O)CC(c2cccnc2)N1Cc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.44
MDM2 Q00987 1/20 0.44
TDP1 Q9NUW8 1/20 0.43
ALDH1A1 P00352 3/20 0.42
MAPT P10636 2/20 0.42
KDM4E B2RXH2 4/20 0.42
LMNA P02545 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
FPR1 P21462 1/20 0.40
TSHR P16473 2/20 0.39
NPSR1 Q6W5P4 2/20 0.39
CYP3A4 P08684 1/20 0.39
THRB P10828 1/20 0.39
THPO P40225 1/20 0.39
MEN1 O00255 1/20 0.39
MAPK1 P28482 1/20 0.39
KMT2A Q03164 1/20 0.39
NPEPPS P55786 1/20 0.39
GAA P10253 1/20 0.39
HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6982043 0.77 TP53 (0.36) TP53MDM2TDP1ALDH1A1KDM4E
SCHEMBL6986921 0.67 KDM4E (0.50) TDP1ALDH1A1MAPTKDM4ELMNA
SCHEMBL6985292 0.67 CHRNB2 (0.41) ALDH1A1MAPTKDM4ETSHRNPSR1
SCHEMBL28508997 0.66 ALDH1A1 (0.72) TP53MDM2TDP1ALDH1A1MAPT
SCHEMBL28502868 0.66 ALDH1A1 (0.72) TP53MDM2TDP1ALDH1A1MAPT
SCHEMBL29683884 0.66 ALDH1A1 (0.72) TP53MDM2TDP1ALDH1A1MAPT
SCHEMBL28503664 0.66 ALDH1A1 (0.72) TP53MDM2TDP1ALDH1A1MAPT
SCHEMBL30116759 0.65 TDP1 (0.53) TP53MDM2TDP1ALDH1A1MAPT
SCHEMBL2569983 0.63 TRPV6 (0.64) TP53MDM2MEN1KMT2A
SCHEMBL24154365 0.63 LMNA (0.47) TDP1ALDH1A1MAPTKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1050530-B1 1-Aza-2-alkyl-6-aryl-cycloalkanes usefull as memory enhancers SERVIER LAB (FR) 2003-10-22 EP disclosed
US-6451789-B1 CENTRAL NERVOUS SYSTEM DISORDERS; COGNITION ACTIVATORS LES LABORTOIRES SERVIER (FR) 2002-09-17 US disclosed
US-20020042413-A1 1-aza-2-alkyl-6-aryl-cycloalkanes RAULT SYLVAIN (FR) 2002-04-11 US disclosed
US-6323222-B1 COGNITION ACTIVATORS, ALZHEIMER*S DISEASE AND ENZYME INHIBITORS ADIR ET COMPAGNIE (FR) 2001-11-27 US disclosed
EP-1050530-A1 1-Aza-2-alkyl-6-aryl-cycloalkanes usefull as memory enhancers ADIR ET COMPAGNIE (FR) 2000-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042413-A1 1-aza-2-alkyl-6-aryl-cycloalkanes SULT2A1, GRIN2A, NR3C1 TP53 3008/4885MDM2 2666/4885TDP1 3048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.